PMID- 22773702
OWN - NLM
STAT- MEDLINE
DCOM- 20130417
LR  - 20220408
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Print)
IS  - 0149-5992 (Linking)
VI  - 35
IP  - 11
DP  - 2012 Nov
TI  - Curcumin extract for prevention of type 2 diabetes.
PG  - 2121-7
LID - 10.2337/dc12-0116 [doi]
AB  - OBJECTIVE: To assess the efficacy of curcumin in delaying development of type 2 
      diabetes mellitus (T2DM) in the prediabetic population. RESEARCH DESIGN AND 
      METHODS: This randomized, double-blinded, placebo- controlled trial included 
      subjects (n = 240) with criteria of prediabetes. All subjects were randomly 
      assigned to receive either curcumin or placebo capsules for 9 months. To assess 
      the T2DM progression after curcumin treatments and to determine the number of 
      subjects progressing to T2DM, changes in beta-cell functions (homeostasis model 
      assessment [HOMA]-beta, C-peptide, and proinsulin/insulin), insulin resistance 
      (HOMA-IR), anti-inflammatory cytokine (adiponectin), and other parameters were 
      monitored at the baseline and at 3-, 6-, and 9-month visits during the course of 
      intervention. RESULTS: After 9 months of treatment, 16.4% of subjects in the 
      placebo group were diagnosed with T2DM, whereas none were diagnosed with T2DM in 
      the curcumin-treated group. In addition, the curcumin-treated group showed a 
      better overall function of beta-cells, with higher HOMA-beta (61.58 vs. 48.72; P < 
      0.01) and lower C-peptide (1.7 vs. 2.17; P < 0.05). The curcumin-treated group 
      showed a lower level of HOMA-IR (3.22 vs. 4.04; P < 0.001) and higher adiponectin 
      (22.46 vs. 18.45; P < 0.05) when compared with the placebo group. CONCLUSIONS: A 
      9-month curcumin intervention in a prediabetic population significantly lowered 
      the number of prediabetic individuals who eventually developed T2DM. In addition, 
      the curcumin treatment appeared to improve overall function of beta-cells, with very 
      minor adverse effects. Therefore, this study demonstrated that the curcumin 
      intervention in a prediabetic population may be beneficial.
FAU - Chuengsamarn, Somlak
AU  - Chuengsamarn S
AD  - Division of Endocrinology and Metabolism, Faculty of Medicine, HRH Princess Maha 
      Chakri Sirindhorn Medical Center, Srinakharinwirot University, Nakornnayok, 
      Thailand. somlukc@hotmail.com
FAU - Rattanamongkolgul, Suthee
AU  - Rattanamongkolgul S
FAU - Luechapudiporn, Rataya
AU  - Luechapudiporn R
FAU - Phisalaphong, Chada
AU  - Phisalaphong C
FAU - Jirawatnotai, Siwanon
AU  - Jirawatnotai S
LA  - eng
SI  - ClinicalTrials.gov/NCT01052025
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20120706
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
RN  - 0 (Plant Extracts)
RN  - IT942ZTH98 (Curcumin)
SB  - IM
CIN - Explore (NY). 2013 Jul-Aug;9(4):251-4. PMID: 23906104
MH  - Curcumin/*therapeutic use
MH  - Diabetes Mellitus, Type 2/*prevention & control
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Plant Extracts/*therapeutic use
MH  - Prediabetic State/*drug therapy
MH  - Treatment Outcome
PMC - PMC3476912
EDAT- 2012/07/10 06:00
MHDA- 2013/04/18 06:00
PMCR- 2013/11/01
CRDT- 2012/07/10 06:00
PHST- 2012/07/10 06:00 [entrez]
PHST- 2012/07/10 06:00 [pubmed]
PHST- 2013/04/18 06:00 [medline]
PHST- 2013/11/01 00:00 [pmc-release]
AID - dc12-0116 [pii]
AID - 0116 [pii]
AID - 10.2337/dc12-0116 [doi]
PST - ppublish
SO  - Diabetes Care. 2012 Nov;35(11):2121-7. doi: 10.2337/dc12-0116. Epub 2012 Jul 6.